Abstract:The peptidoglycan-polysaccharide (PGPS) model shares many etiologic and pathologic features with Crohn's disease (CD).Anti-TNFα therapy reduces both inflammation and fibrosis in the PGPS model if begun early but, as in CD, has diminished efficacy when instituted late in the course of the model.To begin to tease out the mechanism of diminished anti-TNFα efficacy in advanced disease, we examined changes in mRNA levels of a broad panel of proinflammatory and profibrotic factors over time in the PGPS model.Methods: PGPS or human serum albumin (HSA, control) was injected into the bowel wall of Lewis rats at laparotomy.Rats (1 HSA, 3 PGPS) were euthanized at each time point (1, 4, 7, 11, 14, 21, and 28 d post injection).Non-operated rats (3) served as d0 controls.In separate experiments, rats received Ab501 (CA156_00501 Fab'-PEG; a pegylated murinized rabbit anti-mouse TNF) beginning on d1 or d13.Rats receiving anti-TNF were studied on d12 or d28.Gross abdominal score (sum of adhesions, mesenteric thickening, cecal wall thickening, cecal nodules, and liver nodules on 0-4 scales) was determined.A pathologist scored cecal sections.Quantitative real-time PCR was performed on cecal tissue.Results: IL1 β, IL6, TNFα, and TGFβ1 mRNAs showed a biphasic response, peaking at d1 and again at d11 post PGPS injection (previously shown).The second peak at d11 was accompanied by maximal mRNA levels of Th1 (IFNγ, IL2) and Th17 (IL17A) cytokines, IL23, granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1, arginase-1, tissue transglutaminase 2, and tissue inhibitor of metalloproteinase 1. Osteopontin mRNA was maximally elevated at d1 (.500-fold), then progressively declined to ~40-fold control at d21-28.IL13 mRNA was not elevated.Anti-TNF begun on d1 decreased expression of IL1 β (5.5±1.8 v 12.8±1.2,p=0.014) and IL6 (11.2±6.6 v 51.5±7.6,p=0.008) when assessed on day 12. Anti-TNF begun on d13 did not change expression of TNF α, IL1β, IL6 mRNAs; procollagens I and III trended higher on d21 (col I: 23.1±6.2v 11.6±1.9,p=0.07; col III: 14.7±2.1 v 9.14±1.7,p=0.06).Conclusions: The robust Th17 response and increased GM-CSF near the midpoint of the PGPS model time course may render the ongoing immune response no longer controllable by targeting TNF α alone.Blockade of TNF α activity initiated at times in the course of disease when TGF β1 mRNA expression is maximal could exaggerate the results of loss of TNF α inhibitory effects on TGF β profibrotic activity.This could explain why anti-TNFα begun on d13 results in increased collagen mRNA at d21.Decreased tissue compliance, suggested by increased collagen deposition at d7, may play a role in triggering the d7-11 wave of increased profibrotic and proinflammatory factors.Cytokine milleu and tissue factors likely determine the effect of anti-TNF on tissue inflammation and fibrosis.

CPT-11 Activates NLRP3 Inflammasome Through JNK and NF-κB Signalings.

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Irinotecan (Cpt-11)-induced Elevation of Bile Acids Potentiates Suppression of IL-10 Expression.

A Novel Benzo[d]imidazole Derivate Prevents the Development of Dextran Sulfate Sodium-Induced Murine Experimental Colitis Via Inhibition of NLRP3 Inflammasome.

CPT-11 mitigates autoimmune diseases by suppressing effector T cells without affecting long-term anti-tumor immunity

Banxia Xiexin decoction combined with 5‐ASA protects against CPT‐11‐induced intestinal dysfunction in rats via inhibiting TLR4/NF‐κB signaling pathway

P101 Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling

Sa1797 Cell Cycle Arrest, DNA Damage and Remodeling of the Colonic Epithelial Barrier Composition and Function Underlies DSS-Induced Colitis

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis

Targeting Purinergic Receptor P2RX1 Modulates Intestinal Microbiota and Alleviates Inflammation in Colitis

Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea

Atractylenolide I Inhibits NLRP3 Inflammasome Activation in Colitis-Associated Colorectal Cancer via Suppressing Drp1-Mediated Mitochondrial Fission

Cell-penetrating TLR inhibitor peptide alleviates ulcerative colitis by the functional modulation of macrophages

PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Peptostreptococcus Anaerobius enhances dextran sulfate sodium-induced colitis by promoting nf-κB-NLRP3-Dependent macrophage pyroptosis.

Protective effects of IRG1/itaconate on acute colitis through the inhibition of gasdermins-mediated pyroptosis and inflammation response

Targeted V-type peptide-decorated nanoparticles prevent colitis by inhibiting endosomal TLR signaling and modulating intestinal macrophage polarization

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

Cantharidin analogue alleviates dextran sulfate sodium-induced colitis in mice by inhibiting the activation of NF-κB signaling